Preclinical evaluation of second generation PIM inhibitors for the treatment of T-cell acute lymphoblastic leukemia and lymphoma.

T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) are aggressive hematologic malignancies that are currently still treated by high-dose chemotherapy possibly followed by hematopoietic stem cell transplantation.[1][1] Despite important progress in deciphering the